Revenues Disaggregation of Revenues (Tables)

6 Months Ended

Jun. 30, 2019

Disaggregation of Revenue [Abstract]

The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):



	Three Months Ended June 30, 2019								Three Months Ended June 30, 2018
	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
Atripla	$	122	$	26	$	4	$	152	$	274	$	39	$	36	$	349
Biktarvy	1,023		73		20		1,116		183		2		—		185
Complera/Eviplera	42		72		9		123		82		103		14		199
Descovy	246		69		43		358		311		78		14		403
Genvoya	733		177		70		980		904		207		49		1,160
Odefsey	266		111		10		387		303		77		5		385
Stribild	78		24		6		108		144		34		9		187
Truvada	657		41		20		718		649		86		30		765
Other HIV⁽¹⁾	9		1		5		15		11		3		5		19
Revenue share – Symtuza⁽²⁾	55		29		—		84		—		13		—		13
AmBisome	10		60		35		105		14		55		34		103
Ledipasvir/Sofosbuvir⁽³⁾	86		22		85		193		230		22		79		331
Letairis	204		—		—		204		244		—		—		244
Ranexa	19		—		—		19		208		—		—		208
Sofosbuvir/Velpatasvir⁽⁴⁾	219		156		118		493		239		168		93		500
Vemlidy	71		5		40		116		59		3		14		76
Viread	9		28		38		75		16		32		34		82
Vosevi	53		15		7		75		86		20		3		109
Yescarta	99		21		—		120		68		—		—		68
Zydelig	12		14		—		26		17		22		—		39
Other⁽⁵⁾	41		97		2		140		27		41		47		115
Total product sales	4,054		1,041		512		5,607		4,069		1,005		466		5,540
Royalty, contract and other revenues	19		58		1		78		14		79		15		108
Total revenues	$	4,073	$	1,099	$	513	$	5,685	$	4,083	$	1,084	$	481	$	5,648



	Six Months Ended June 30, 2019								Six Months Ended June 30, 2018
	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
Atripla	$	255	$	42	$	26	$	323	$	502	$	90	$	71	$	663
Biktarvy	1,762		121		26		1,909		218		2		—		220
Complera/Eviplera	86		134		18		238		149		212		28		389
Descovy	479		137		84		700		585		153		26		764
Genvoya	1,461		370		164		1,995		1,757		393		92		2,242
Odefsey	548		217		19		784		582		135		10		727
Stribild	145		42		17		204		277		63		21		361
Truvada	1,208		74		42		1,324		1,156		183		78		1,417
Other HIV⁽¹⁾	20		2		10		32		20		4		8		32
Revenue share – Symtuza⁽²⁾	97		53		—		150		—		20		—		20
AmBisome	18		117		63		198		31		111		68		210
Ledipasvir/Sofosbuvir⁽³⁾	203		49		166		418		464		78		137		679
Letairis	401		—		—		401		448		—		—		448
Ranexa	174		—		—		174		403		—		—		403
Sofosbuvir/Velpatasvir⁽⁴⁾	449		310		225		984		508		366		162		1,036
Vemlidy	136		9		72		217		106		6		22		134
Viread	21		42		84		147		23		62		94		179
Vosevi	98		31		9		138		172		36		8		216
Yescarta	189		27		—		216		108		—		—		108
Zydelig	23		29		1		53		31		40		1		72
Other⁽⁵⁾	77		117		8		202		56		56		109		221
Total product sales	7,850		1,923		1,034		10,807		7,596		2,010		935		10,541
Royalty, contract and other revenues	41		114		4		159		34		131		30		195
Total revenues	$	7,891	$	2,037	$	1,038	$	10,966	$	7,630	$	2,141	$	965	$	10,736



____________________
Notes:
(1)	Includes Emtriva and Tybost
(2)	Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC (Janssen)
(3)	Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC
(4)	Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC
(5)	Includes Cayston, Hepsera and Sovaldi